Investigational Drug Information for GS-9674
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the drug development status for GS-9674?
GS-9674 is an investigational drug.
There have been 11 clinical trials for GS-9674. The most recent clinical trial was a Phase 2 trial, which was initiated on March 27th 2019.
The most common disease conditions in clinical trials are Fatty Liver, Non-alcoholic Fatty Liver Disease, and Cholangitis. The leading clinical trial sponsors are Gilead Sciences, Novo Nordisk A/S, and [disabled in preview].
There are eight US patents protecting this investigational drug and one hundred and twenty-seven international patents.
Summary for GS-9674
|US Patent Applications||19|
|WIPO Patent Applications||9|
|Japanese Patent Applications||0|
|Clinical Trial Progress||Phase 2 (2019-03-27)|
Recent Clinical Trials for GS-9674
|Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)||Novo Nordisk A/S||Phase 2|
|Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)||Gilead Sciences||Phase 2|
|Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis||Gilead Sciences||Phase 1|
Clinical Trial Summary for GS-9674
Top disease conditions for GS-9674
Top clinical trial sponsors for GS-9674
US Patents for GS-9674
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GS-9674||See Plans and Pricing||FXR agonists and methods for making and using||Salk Institute for Biological Studies (La Jolla, CA)||See Plans and Pricing|
|GS-9674||See Plans and Pricing||FXR (NR1H4) binding and activity modulating compounds||GILEAD SCIENCES, INC. (Foster City, CA)||See Plans and Pricing|
|GS-9674||See Plans and Pricing||FXR (NR1H4) modulating compounds||Gilead Sciences, Inc. (Foster City, CA)||See Plans and Pricing|
|GS-9674||See Plans and Pricing||Acyclic antivirals||Janssen BioPharma, Inc. (South San Francisco, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
International Patents for GS-9674
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|GS-9674||Australia||AU2015229072||2034-03-13||See Plans and Pricing|
|GS-9674||Canada||CA2942403||2034-03-13||See Plans and Pricing|
|GS-9674||European Patent Office||EP3116878||2034-03-13||See Plans and Pricing|
|GS-9674||Japan||JP2017510572||2034-03-13||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|